{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:21:03Z","timestamp":1772839263635,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s12029-021-00738-3","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T03:02:52Z","timestamp":1637118172000},"page":"1028-1033","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic Value of International Normalized Ratio-to-Albumin Ratio and Ferritin Level in Chronic Liver Patients with Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"53","author":[{"given":"Yakup","family":"\u00dclger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An\u0131l","family":"Delik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"738_CR1","unstructured":"International Agency for Research on Cancer. GLOBOCAN\u00a0IARC. 2018.\u00a0https:\/\/gco.iarc.fr\/today\/online-analysis-map?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=11&type=0&statistic=5&prevalence=0&population_groupearth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&rotate=%255B10%252C0%255D"},{"key":"738_CR2","doi-asserted-by":"crossref","unstructured":"Llovet JM, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2016;2:16018.","DOI":"10.1038\/nrdp.2016.18"},{"key":"738_CR3","doi-asserted-by":"crossref","unstructured":"Haruki K, et al. Risk stratification using a novel liver functional reserve score of combination prothrombin time\u2013international normalized ratio to albumin ratio and albumin in patients with hepatocellular carcinoma.\u00a0Surgery.\u00a02018;164.3:404\u2013410.","DOI":"10.1016\/j.surg.2018.02.022"},{"issue":"1","key":"738_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12906-018-2240-7","volume":"18","author":"A Song","year":"2018","unstructured":"Song A, Eo W, Kim S, Shim B, Lee S. Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study. BMC Complement Altern Med. 2018;18(1):1\u201310.","journal-title":"BMC Complement Altern Med"},{"key":"738_CR5","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer, EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.\u00a0J Hepatol.\u00a02012;56(4):908\u2013943.","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"738_CR6","doi-asserted-by":"crossref","unstructured":"The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology.\u00a01998;28(3):751\u2013755.","DOI":"10.1002\/hep.510280322"},{"issue":"6","key":"738_CR7","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/hep.20486","volume":"40","author":"M Kudo","year":"2004","unstructured":"Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40(6):1396\u2013405.","journal-title":"Hepatology"},{"issue":"2","key":"738_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","volume":"33","author":"PS Kamath","year":"2001","unstructured":"Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology.\u00a02001;33(2):464\u201370.","journal-title":"Hepatology"},{"issue":"2","key":"738_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1440-1746.2010.06329.x","volume":"26","author":"SL Chan","year":"2011","unstructured":"Chan SL, Mo FKF, Johnson PJ, et al. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol. 2011;26(2):340\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"738_CR10","doi-asserted-by":"crossref","unstructured":"Chan, Anthony WH, et al. Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. Dis Markers. 2015;564057","DOI":"10.1155\/2015\/564057"},{"key":"738_CR11","doi-asserted-by":"crossref","unstructured":"Li, Leung, et al. The association of liver function and quality of life of patients with liver cancer.\u00a0BMC Gastroenterol.\u00a02019;19:1\u201312.","DOI":"10.1186\/s12876-019-0984-2"},{"issue":"8","key":"738_CR12","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1038\/bjc.2014.130","volume":"110","author":"R Fox","year":"2014","unstructured":"Fox R, Berhane S, Teng M, Cox T, Tada T, Toyoda H, Kumada T, Kagebayashi C, Satomura S, Johnson PJ. Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model. Br J Cancer. 2014;110(8):2090\u20138.","journal-title":"Br J Cancer"},{"issue":"1","key":"738_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/gut.48.1.103","volume":"48","author":"M Schoniger-Hekele","year":"2001","unstructured":"Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001;48(1):103\u20139.","journal-title":"Gut"},{"key":"738_CR14","doi-asserted-by":"crossref","unstructured":"Wu SJ, Lin YX, Ye H, Xiong XZ, Li FY, Cheng NS. Prognostic value of alkaline phosphatase, gamma-glutamyl transpeptidase and lactate dehydrogenase in hepatocellular carcinoma patients treated with liver resection. Int J Surg. 2016;36(Pt A:143\u201351.","DOI":"10.1016\/j.ijsu.2016.10.033"},{"issue":"11","key":"738_CR15","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/jgh.12310","volume":"28","author":"HY Kim","year":"2013","unstructured":"Kim HY, Park JW, Joo J, Kim H, Woo SM, Lee WJ, Kim CM. Worse outcome of sorafenib therapy associated with ascites and child-Pugh score in advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28(11):1756\u201361.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"738_CR16","first-page":"1114","volume":"7","author":"J Xiao","year":"2014","unstructured":"Xiao J, Li G, Lin S, He K, Lai H, Mo X, Chen J, Lin Y. Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization. Int J Clin Exp Pathol. 2014;7(3):1114\u201323.","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"738_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O\u2019Beirne J, Fox R, Skowronska A, Palmer D, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"738_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/hepr.12796","volume":"47","author":"MX Li","year":"2017","unstructured":"Li MX, Zhao H, Bi XY, Li ZY, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Cai JQ. Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma: validation in a Chinese cohort. Hepatol Res. 2017;47(8):731\u201341.","journal-title":"Hepatol Res"},{"issue":"1","key":"738_CR19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/hep.29468","volume":"67","author":"RJ de Haas","year":"2018","unstructured":"de Haas RJ, Lim C, Bhangui P, Salloum C, Compagnon P, Feray C, Calderaro J, Luciani A, Azoulay D. Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: an intention-to-treat analysis. Hepatology. 2018;67(1):204\u201315.","journal-title":"Hepatology"},{"key":"738_CR20","doi-asserted-by":"crossref","unstructured":"Yu YQ, Li J, Liao Y, Chen Q, Liao WJ, Huang J. The preoperative alkaline phosphatase-to-platelet ratio index is an independent prognostic factor for hepatocellular carcinoma after hepatic resection. Medicine (Baltimore). 2016;95(51):e5734.","DOI":"10.1097\/MD.0000000000005734"},{"key":"738_CR21","doi-asserted-by":"crossref","unstructured":"Chan AW, Chan SL, Mo FK, Wong GL, Wong VW, Cheung YS, Chan HL, Yeo W, Lai PB, To KF. Albumin-to-alkaline phosphatase ratio: a novel prognostic index for hepatocellular carcinoma. Dis Markers. 2015;2015:564057.","DOI":"10.1155\/2015\/564057"},{"issue":"20","key":"738_CR22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4254\/wjh.v9.i20.867","volume":"9","author":"L Li","year":"2017","unstructured":"Li L, Yeo W. Value of quality of life analysis in liver cancer: a clinician\u2019s perspective. World J Hepatol. 2017;9(20):867\u201383.","journal-title":"World J Hepatol"},{"key":"738_CR23","doi-asserted-by":"crossref","unstructured":"Oikonomou T, et al. The significance of C-reactive protein to albumin ratio in patients with decompensated cirrhosis.\u00a0Ann Gastroenterol.\u00a02020;33(6):667.","DOI":"10.20524\/aog.2020.0534"},{"issue":"12","key":"738_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051379","volume":"7","author":"AA Alkhateeb","year":"2012","unstructured":"Alkhateeb AA, Leitzel K, Ali SM, Campbell-Baird C, Evans M, Fuchs EM, et al. Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy. PLoS ONE. 2012;7(12): e51379. https:\/\/doi.org\/10.1371\/journal.pone.0051379.","journal-title":"PLoS ONE"},{"issue":"3","key":"738_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10549-012-2405-x","volume":"137","author":"AA Alkhateeb","year":"2013","unstructured":"Alkhateeb AA, Han B, Connor JR. Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages. Breast Cancer Res Treat. 2013;137(3):733\u201344. https:\/\/doi.org\/10.1007\/s10549-012-2405-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"738_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.24706","volume":"55","author":"KV Kowdley","year":"2012","unstructured":"Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(1):77\u201385. https:\/\/doi.org\/10.1002\/hep.24706.","journal-title":"Hepatology"},{"issue":"11","key":"738_CR27","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1111\/jgh.12618","volume":"29","author":"A Facciorusso","year":"2014","unstructured":"Facciorusso A, Del Prete V, Antonino M, Neve V, Crucinio N, Di Leo A, et al. Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. J Gastroenterol Hepatol. 2014;29(11):1905\u201310. https:\/\/doi.org\/10.1111\/jgh.12618.","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"738_CR28","doi-asserted-by":"publisher","first-page":"10195","DOI":"10.1007\/s13277-014-2317-y","volume":"35","author":"M Ji","year":"2014","unstructured":"Ji M, Li XD, Shi HB, Ning ZH, Zhao WQ, Wang Q, et al. Clinical significance of serum ferritin in elderly patients with primary lung carcinoma. Tumour Biol. 2014;35(10):10195\u20139. https:\/\/doi.org\/10.1007\/s13277-014-2317-y.","journal-title":"Tumour Biol"},{"key":"738_CR29","doi-asserted-by":"publisher","unstructured":"Kalousova M, Krechler T, Jachymova M, Kubena AA, Zak A, Zima T. Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study.\u00a0Tumour Biol.\u00a02012;33(5):1695\u20131700.\u00a0https:\/\/doi.org\/10.1007\/s13277-012-0426-z.","DOI":"10.1007\/s13277-012-0426-z"},{"issue":"1","key":"738_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/ijlh.12592","volume":"39","author":"S Koyama","year":"2017","unstructured":"Koyama S, Fujisawa S, Watanabe R, Itabashi M, Ishibashi D, Ishii Y, et al. Serum ferritin level is a prognostic marker in patients with peripheral T-cell lymphoma. Int J Lab Hematol. 2017;39(1):112\u20137. https:\/\/doi.org\/10.1111\/ijlh.12592.","journal-title":"Int J Lab Hematol"},{"issue":"8","key":"738_CR31","doi-asserted-by":"publisher","first-page":"957","DOI":"10.7150\/jca.14797","volume":"7","author":"S Lee","year":"2016","unstructured":"Lee S, Song A, Eo W. Serum ferritin as a prognostic biomarker for survival in relapsed or refractory metastatic colorectal Cancer. J Cancer. 2016;7(8):957\u201364. https:\/\/doi.org\/10.7150\/jca.14797.","journal-title":"J Cancer"},{"issue":"43","key":"738_CR32","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.3748\/wjg.v21.i43.12410","volume":"21","author":"A Song","year":"2015","unstructured":"Song A, Eo W, Lee S. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients. World J Gastroenterol. 2015;21(43):12410\u201320. https:\/\/doi.org\/10.3748\/wjg.v21.i43.12410.","journal-title":"World J Gastroenterol"},{"key":"738_CR33","doi-asserted-by":"crossref","unstructured":"Shen J, Tang L, Zhang X, Peng W, Wen T, Li C, et al. A novel index in hepatocellular carcinoma patients after curative hepatectomy: albumin to gamma-glutamyltransferase ratio (AGR).\u00a0Front Oncol.\u00a02019;9:817.","DOI":"10.3389\/fonc.2019.00817"},{"key":"738_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1634\/theoncologist.2015-0284","volume":"21","author":"O K\u00f6nigsbr\u00fcgge","year":"2016","unstructured":"K\u00f6nigsbr\u00fcgge O, Posch F, Riedl J, Reitter EM, Zielinski C, Pabinger I, et al. Association between ecreased serum albumin with risk of venous thromboembolism and mortality in cancer patients. Oncologist. 2016;21:252\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2015-0284.","journal-title":"Oncologist"},{"key":"738_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/carcin\/bgu247","volume":"36","author":"X Liu","year":"2015","unstructured":"Liu X, Meng QH, Ye Y, Hildebrandt MA, Gu J, Wu X. Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. Carcinogenesis. 2015;36:243\u20138. https:\/\/doi.org\/10.1093\/carcin\/bgu247.","journal-title":"Carcinogenesis"},{"key":"738_CR36","doi-asserted-by":"publisher","first-page":"13293","DOI":"10.18632\/oncotarget.14530","volume":"8","author":"CY Jing","year":"2017","unstructured":"Jing CY, Fu YP, Shen HJ, Zheng SS, Lin JJ, Yi Y, et al. Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection. Oncotarget. 2017;8:13293\u2013303. https:\/\/doi.org\/10.18632\/oncotarget.14530.","journal-title":"Oncotarget"},{"issue":"4","key":"738_CR37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.20892\/j.issn.2095-3941.2016.0063","volume":"13","author":"XD Xun","year":"2016","unstructured":"Xun XD, Li Q. Surgical treatment of intrahepatic cholangiocarcinoma: a retrospective study of 104 cases. Cancer Biol Med. 2016;13(4):469\u201373. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0063.","journal-title":"Cancer Biol Med"},{"key":"738_CR38","doi-asserted-by":"crossref","unstructured":"Vohra I, et al. Evaluation of ferritin and transferrin ratio as a prognostic marker for hepatocellular carcinoma.\u00a0J\u00a0Gastrointest\u00a0Cancer.\u00a02021;52(1):201\u2013206.","DOI":"10.1007\/s12029-020-00373-4"},{"key":"738_CR39","doi-asserted-by":"crossref","unstructured":"Yang H-J, et al. Preoperative platelet-to-lymphocyte ratio is a valuable prognostic biomarker in patients with hepatocellular carcinoma undergoing curative liver resection.\u00a0Tumor Biol.\u00a02017;39(6):1010428317707375.","DOI":"10.1177\/1010428317707375"},{"key":"738_CR40","doi-asserted-by":"crossref","unstructured":"Huang XZ, Chen WJ, Zhang X, Wu CC, Zhang CY, Sun SS, et al. An elevated platelet-to-lymphocyte ratio predicts poor prognosis and clinicopathological characteristics in patients with colorectal cancer: a meta-analysis. Dis Markers. 2017;1053125","DOI":"10.1155\/2017\/1053125"},{"key":"738_CR41","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1245\/s10434-014-4048-0","volume":"22","author":"A Kinoshita","year":"2015","unstructured":"Kinoshita A, Onoda H, Imai N, et al. The C-reactive protein\/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2015;22:803\u201310.","journal-title":"Ann Surg Oncol"},{"key":"738_CR42","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/MEG.0000000000000807","volume":"29","author":"SS Huang","year":"2017","unstructured":"Huang SS, Xie DM, Cai YJ, et al. C-reactive protein-to-albumin ratio is a predictor of hepatitis B virus related decompensated cirrhosis: time-dependent receiver operating characteristics and decision curve analysis. Eur J Gastroenterol Hepatol. 2017;29:472\u201380.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-021-00738-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-021-00738-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-021-00738-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T19:23:18Z","timestamp":1667416998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-021-00738-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1007\/s12029-021-00738-3","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"19 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}